CINC · Cincor Pharma, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q4 '20 | Q4 '19 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| R&D | $17.73M | $17.16M | $3.49M | - | - | - |
| SG&A | $4.52M | $1.18M | $4.03M | - | - | - |
| Total Operating Expenses | $22.24M | $5.17M | $13.70M | - | - | - |
| D&A | - | - | - | - | - | - |
| Operating Income | ($22.24M) | ($5.17M) | ($13.70M) | - | - | - |
| Interest Expense | - | - | - | - | - | - |
| Income Tax | - | - | - | - | - | - |
| Net Income | ($9.02M) | ($6.38M) | ($5.62M) | - | - | - |
| EPS - Basic | ($5.19) | ($4.81) | - | - | - | - |
| EPS - Diluted | ($5.19) | - | - | - | - | - |
Balance Sheet
| Line item | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q4 '20 | Q4 '19 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $292.56M | $127.62M | $164.60M | $136.61M | $26.08M | $11.48M |
| Accounts Receivable | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Accounts Payable | $2.59M | $2.10M | $4.37M | $642.1K | $3.67M | - |
| Current Assets | $529.02M | $302.98M | $321.65M | $141.11M | $26.80M | - |
| Total Assets | $529.12M | $303.02M | $321.65M | $141.11M | $26.80M | - |
| Current Liabilities | $10.18M | $7.28M | $5.69M | $16.55M | $6.89M | - |
| Long-term Debt | - | - | - | - | - | - |
| Total Liabilities | - | - | - | - | - | - |
| Stockholders' Equity | ($44.81M) | $295.73M | $315.96M | ($63.72M) | ($27.26M) | ($4.98M) |
| Retained Earnings | ($136.45M) | ($115.48M) | ($94.40M) | ($77.70M) | ($27.33M) | - |
Cash Flow
| Line item | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q4 '20 | Q4 '19 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | ($5.77M) | - | - | - |
| Investing Cash Flow | - | - | ($149.84M) | - | - | - |
| Financing Cash Flow | - | - | $195.55M | - | - | - |
| CapEx | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - |
Ratios
| Metric | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q4 '20 | Q4 '19 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - |
| R&D / Revenue | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - |
| Return on assets | -1.7% | -2.1% | -1.7% | - | - | - |
| Return on equity | 20.1% | -2.2% | -1.8% | - | - | - |
| Return on invested capital | - | - | - | - | - | - |
| Liquidity | ||||||
| Current ratio | 51.96 | 41.61 | 56.57 | 8.53 | 3.89 | - |
| Quick ratio | 51.96 | 41.61 | 56.57 | 8.53 | 3.89 | - |
| Cash ratio | 28.73 | 17.53 | 28.95 | 8.25 | 3.78 | - |
| Leverage | ||||||
| Debt / Equity | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - |
| Equity multiplier | -11.81 | 1.02 | 1.02 | -2.21 | -0.98 | - |
| Liabilities / Assets | - | - | - | - | - | - |
| Efficiency | ||||||
| Asset turnover | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - |
| Operating income growth (YoY) | - | - | - | - | - | - |
| Net income growth (YoY) | - | - | - | - | - | - |
| EPS growth (YoY) | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | - | - | - | -133.7% | -447.3% | - |
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing CinCor Pharma against the 5 most active filers in the same SIC group.